Genmab — Maj 2017
-
Under Q&A bemærkede jeg iøvrigt hvor hurtigt Jan koblede Daratumumab på PD- L1 og Limo Chen. Kunne tolkes som at det var Dara Limo anvendte. Jans henvisning til Chevrier understreger også CD38's rolle mht macrophages og T cells. http://www.cell.com/cell/fulltext/S0092-8674(17)30429-4
-
God morgen. Her er en ny retning for Genmab forskning. Blocker antibody: https://www.nature.com/articles/s41598-017-01019-5
-
God morgen.
-
Sådan er det desværre i perioder. Forude venter dog J&J dag, salgstal og ASH.
-
Johnson & Johnson Pharmaceutical Business Review den 17. maj fra 14:30 til 20:30 kan følges på webcast https://www.jnj.com/media-center/press-releases/johnson-johnson-to-host-pharmaceutical-business-review-2017
-
Der var en interessant artikel omkring pipeline http://borsen.dk/nyheder/virksomheder/artikel/1/345163/genmab-boss_paa_aggressiv_kurs_i_aar_vil_vi_fordoble_vores_egen_pipeline.html
. Hvis Genmap kan realisere det, de her har sat sig for. Vil der helt sikkert være en styrket interesse, da enkelte af de store spillere mangler, nye præparater i deres pipeline -
Ingen konkrete stoffer henvises men. Mere en general strategisk betragtning og herunder også ansættelsen af Judith Klimovsky, som udviklingschef
-
Sorry..JohnW.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind